Showing results (151-160 of 227) with videos related to
Sort By:
Pageof 23
Science Translational Medicine|June 5, 2024
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimeticsFelix Korell, Michael L Olson, Diego Salas-Benito, et al.Cytometry. Part B, Clinical Cytometry|February 28, 2024
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral bloodWon-Ho Lee, Charlotte E Graham, Hadley R Wiggin, et al.Journal for Immunotherapy of Cancer|September 10, 2025
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a timeDiego Salas-Benito, Filippo Birocchi, Sangwoo Park, et al.Leukemia|July 31, 2025
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphomaTayla B Heavican-Foral, Felix Korell, Irene Scarfò, et al.Cell Chemical Biology|November 21, 2023
Genetic retargeting of E3 ligases to enhance CAR T cell therapyIsabel C Lane, Gabriele Kembuan, Jeannie Carreiro, et al.Blood|November 21, 2024
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLHarrison J Silva, Grace Martin, Filippo Birocchi, et al.Nature Communications|May 9, 2019
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor responsePatrick A Baeuerle, Jian Ding, Ekta Patel, et al.The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.Journal for Immunotherapy of Cancer|November 16, 2019
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastomaBryan D Choi, Xiaoling Yu, Ana P Castano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaMarco Ruella, Saad S Kenderian, Olga Shestova, et al.Pageof 23